Acoramidis reduced incidence of atrial fibrillation events in patients with attr-cm

- in a post-hoc analysis of attribute-cm, acoramidis reduced the annual frequency of cvh due to af/afl by 43% compared to placebo and reduced the incidence of new-onset af/afl by 17% in the subgroup with no prior history of af compared to placebo
AFL Ratings Summary
AFL Quant Ranking